Market Newsdesk

December 11, 2020 2:48 am

Unibail-Rodamco-Westfield’s ambitious carbon reduction targets recognized by the Science Based Targets initiative (SBTi)

Paris, Amsterdam, December 11, 2020

Press release

Unibail-Rodamco-Westfield’s ambitious carbon reduction targets recognized by the Science Based Targets initiative (SBTi)

Unibail-Rodamco-Westfield (URW) is pleased to announce the greenhouse gas (GHG) emissions reduction targets of its “Better Places 2030” CSR strategy have been approved by the Science Based Targets initiative (SBTi) as consistent with levels required to meet the goals of the Paris Agreement:

URW’s targets covering emissions from the Group’s operations (scopes 1 and 2) are consistent with reductions required to maintain global warming under 1.5°C, the most ambitious goal of the Paris Agreement.
URW’s emissions target pertaining to its value chain (scope 3) meet the SBTi’s criteria for ambitious value chain goals, corresponding to the current best practices.

The SBTi is a collaboration between the Carbon Disclosure Project (CDP), the United Nations Global Compact, the World Resources Institute (WRI) and the World Wide Fund for Nature (WWF). The SBTi defines and promotes best practices in science-based target setting and independently assesses companies’ targets.

As part of “Better Places 2030”, URW has taken a strong commitment on climate change. On top of the SBTi recognition of its GHG emissions reduction targets, the Group has joined the Business Ambition for 1.5°C campaign. The Group’s leadership on climate change has once again been recognized by the CDP in its 2020 Climate Change assessment. For the third year in a row, URW achieved a score of “A”, the highest in this assessment. This top ranking confirms the relevance of URW’s climate change strategy and results achieved so far.

In 2016, URW defined an ambitious Corporate Social Responsibility (CSR) strategy, “Better Places 2030”, addressing the main challenges facing commercial real estate. This CSR ambition is integrated in all key decision-making processes, from the design of development projects to the construction, from everyday maintenance to regular improvements, from the relationship with retailers to the final experience provided to visitors. This approach fully integrates local authorities, start-ups, industry leaders, and the local communities. As part of Better Places 2030, URW committed to reduce by -50% its emissions across the value chain by 2030 in comparison with 2015 levels (-35% on construction, -80% on operations and -40% on transportation of visitors).

Julie Villet, Director of URW Lab and Group CSR, said: “The next few years are critical to achieve the ambitious objectives laid out by the Paris Agreement. As a leading commercial Real Estate player, we have a vital role to transform the industry at the pace and scale needed”.

For further information, please contact:

Investor Relations

Samuel Warwood
Maarten Otte
+33 1 76 77 58 02
[email protected]

Media Relations

Céline van Steenbrugghe
+33 6 71 89 73 08
[email protected]

About Unibail-Rodamco-Westfield

Unibail-Rodamco-Westfield is the premier global developer and operator of Flagship Destinations, with a portfolio valued at €58.3 Bn as at September 30, 2020, of which 86% in retail, 7% in offices, 5% in convention & exhibition venues and 2% in services. Currently, the Group owns and operates 89 shopping centres, including 55 Flagships in the most dynamic cities in Europe and the United States. Its centres welcome 1.2 billion visits per year. Present on two continents and in 12 countries, Unibail-Rodamco-Westfield provides a unique platform for retailers and brand events and offers an exceptional and constantly renewed experience for customers.
With the support of its 3,400 professionals and an unparalleled track-record and know-how, Unibail-Rodamco-Westfield is ideally positioned to generate superior value and develop world-class projects.
Unibail-Rodamco-Westfield distinguishes itself by its Better Places 2030 agenda, that sets its ambition to create better places that respect the highest environmental standards and contribute to better cities.
Unibail-Rodamco-Westfield stapled shares are listed on Euronext Amsterdam and Euronext Paris (Euronext ticker: URW), with a secondary listing in Australia through Chess Depositary Interests. The Group benefits from an BBB+ rating from Standard & Poor’s and from a Baa1 rating from Moody’s.

For more information, please visit www.urw.com
Visit our Media Library at https://mediacentre.urw.com
Follow the Group updates on Twitter @urw_group, Linkedin @Unibail-Rodamco-Westfield and Instagram @urw_group

Attachment

Unibail-Rodamco-Westfield’s ambitious carbon reduction targets recognized by the Science Based Targets initiative (SBTi)

December 11, 2020 2:35 am

Adverty partners with InMobi, further strengthening in-game advertising’s programmatic reach

PR Newswire

STOCKHOLM, Dec. 11, 2020 /PRNewswire/ — Adverty AB (publ) announces partnership with global mobile-first advertising technology company InMobi to enable more advertisers to leverage market-leading programmatic in-game offering. The partnership is set to launch during Q1 2021, once the technical integration of platforms has been completed.

Adverty, the leading in-game platform for advertisers, agencies and content creators, has announced a partnership with global ad exchange, InMobi, in order to increase its programmatic reach for brands and advertisers looking to enter the increasingly important world of gaming.

Adverty delivers unobtrusive advertising which connects brands and audiences through its revolutionary and patented technology built specifically for gaming, while InMobi’s industry leading mobile marketing technology is connected to every relevant programmatic DSP allowing advertisers and publishers to engage consumers through contextual mobile advertising. The partnership will allow its buy-side clients to access innovative formats in mobile games at scale within Adverty’s platform. The partnership is set to launch during Q1 2021, once the technical integration of platforms has been completed.

“There is significant demand for Adverty’s seamless in-game inventory at scale and this development enables our team to bring it to a wider range of brands and agencies,” says Niklas Bakos, CEO of Adverty. “Advertisers are certainly waking up to the untapped potential of this burgeoning media channel.”

Earlier this year, Adverty launched a world-first In-Menu™ format, which enables deeply integrated, contextually relevant IAB display banner ads in between gameplay. This latest offering enhances a highly innovative product suite that also allows brands and programmatic partners to take over billboards and other virtual outdoor sites within games thanks to its In-Play™ offerings.

“As the leading global independent advertising platform across mobile apps, mobile websites and connected TV, InMobi has enabled the world’s biggest brand advertisers to connect with audiences through the apps they use everyday,” said David Di Angelo, VP of Marketplace Development at InMobi. “With this new partnership with Adverty, InMobi is able to provide even more opportunities for brands to effectively reach and engage with premium gaming audiences through non-intrusive in-game ads that blend seamlessly into the gaming experience.”

Industry figures are increasingly recognising gaming’s importance as one of the most significant entertainment media channels. The latest figures from games analytics provider, NewZoo, show that the global gaming market currently comprises some 2.7 billion users, valued at USD 160 billion – and it is expected to reach 3.1 billion users and a value of over USD 200 billion by 2023.

There is therefore a huge opportunity for forward-thinking brands to leverage this market with programmatic advertising – mindful of the fact that programmatic ad transactions now make up 84.5% of the digital display ad market, with a total estimated spend of $80 billion in the US alone next year, according to eMarketer.

For further information, please contact:

Niklas Bakos, CEO
Phone: +46 733 28 1110
E-mail: [email protected]

This information is information that Adverty AB (publ) is obliged to disclose under the EU Market Abuse Regulation. The information was provided, through the contact of the above contact person, for publication on the 11^th of December 2020.

Augment Partners AB, phone +46 8-505 65 172, act as certified advisor/mentor for the company at NGM Nordic SME.

About Adverty

Adverty, the leading in-game platform, delivers seamless advertising to connect brands and people through its revolutionary display advertising technology built for games. The platform offers true in-game ad inventory at scale and allows content creators to monetise the complete experience with unobtrusive, easy-to-integrate, immersive ads. Founded in 2016, Adverty has offices in Stockholm, London and Lviv and works with advertisers, agencies and developers to unlock audiences and gaming revenue streams. More information at www.adverty.com.

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/adverty-ab/r/adverty-partners-with-inmobi–further-strengthening-in-game-advertising-s-programmatic-reach,c3252901

The following files are available for download:

https://mb.cision.com/Main/17527/3252901/1347076.pdf

Release

View original content:http://www.prnewswire.com/news-releases/adverty-partners-with-inmobi-further-strengthening-in-game-advertisings-programmatic-reach-301191021.html

SOURCE Adverty AB

December 11, 2020 2:25 am

NANOBIOTIX Announces Pricing of Global Offering and Approval to List on NASDAQ Global Select Market

NANOBIOTIX Announces Pricing of Global Offering and Approval to List on NASDAQ Global Select Market

PARIS & CAMBRIDGE, Mass.–(BUSINESS WIRE)–
Regulatory News:

NANOBIOTIX (Paris:NANO) (Euronext: NANO – ISIN : FR0011341205 – the ‘‘Company’’), a clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, today announced the pricing of its initial public offering on the Nasdaq Global Select Market by way of a capital increase of 7,300,000 new ordinary shares (the “New Shares”), consisting of a public offering of 5,445,000 ordinary shares in the form of American Depositary Shares (“ADSs”), each representing the right to receive one ordinary share, in the United States (the “U.S. Offering”) and a concurrent offering of 1,855,000 ordinary shares in certain jurisdictions outside of the United States to certain investors (the “European Offering” and together with the U.S. Offering, the “Global Offering”). The offering price was set at $13.50 per ADS in the U.S. Offering and a corresponding offering price of €11.14 per New Share based on an exchange rate of €1.00 = $1.2115 as published by the European Central Bank on December 10, 2020. The aggregate gross proceeds are expected to be approximately $98.6 million, equivalent to approximately €81.3 million, before deduction of underwriting commissions and estimated expenses payable by the Company. The Global Offering is expected to close on December 15, 2020, subject to the satisfaction of customary closing conditions.

All the securities sold in the Global Offering will be issued by the Company. The ADSs have been approved for listing on the Nasdaq Global Select Market and are expected to begin trading on December 11, 2020 under the ticker symbol “NBTX.” The Company’s ordinary shares are listed on the regulated market of Euronext Paris under the ticker symbol “NANO.”

The New Shares (some of which are represented by ADSs) sold in the Global Offering will be subject to an application for admission to trading on the regulated market of Euronext in Paris (Compartment B) on the same trading line as the existing shares under the same ISIN code FR0011341205 and are expected to be admitted to trading on December 15, 2020.

Jefferies LLC is acting as global coordinator and joint book-running manager for the Global Offering, and Evercore Group, L.L.C. and UBS Securities LLC are acting as joint book-running managers for the U.S. Offering. Gilbert Dupont is acting as manager for the European Offering (together, the “Underwriters”).

Type of Offering

The New Shares will be issued through a capital increase without shareholders’ preferential subscription rights by way of a public offering and under the provisions of Article L.225-136 of the French Commercial Code (Code de commerce) and pursuant to the 2^nd and 7^th resolutions of the Company’s extraordinary general shareholders’ meeting held on November 30, 2020.

The offering price per New Share in euros is equal to the volume weighted average price of the Company’s ordinary shares on the regulated market of Euronext in Paris over the last three trading days preceding the start of the offering (i.e., December 7, 8 and 9, 2020), minus a discount of 9.80%, and has been determined by the Company pursuant to the 2^nd resolution of the Company’s extraordinary general shareholders’ meeting held on November 30, 2020.

Option to Purchase Additional Shares

The Company has granted the Underwriters an option to purchase (the “Underwriters’Option”), for a 30-day period (until January 9, 2021), up to 1,095,000 additional ADSs, which represents 15% of the aggregate amount of the New Shares to be issued in the Global Offering, at the same offering price.

Stabilization

In connection with the Global Offering, Jefferies LLC, acting as stabilization agent, may over-allot the securities or effect transactions with a view to supporting, stabilizing, or maintaining the market price of the securities at a level higher than which might otherwise prevail in the open market. However, there is no assurance that the stabilization agent will take any stabilization action and, if begun, may be ended at any time without prior notice. Any stabilization action or over-allotment shall be carried out in accordance with all applicable rules and regulations and may be undertaken on the regulated market of Euronext in Paris and on the Nasdaq Global Select Market.

Dilution

The 7,300,000 New Shares to be issued in the Global Offering (5,445,000 of which are ordinary shares represented by ADSs) will result in a dilution of approximately 28% of the Company’s outstanding share capital on a non-diluted basis excluding the exercise of the Underwriters’ Option, and approximately 32% of the Company’s outstanding share capital on a non-diluted basis, in the case of a full exercise of the Underwriters’ Option.

Estimated Proceeds from the Global Offering

The gross proceeds of the issuance of the New Shares are expected to be approximately $98.6 million (€81.3 million), assuming no exercise of the Underwriters’ Option.

The Company estimates that the net proceeds of the Global Offering will be approximately $86.7 million (€71.5 million), after deducting approximately $6.9 million (€5.7 million) in underwriting commissions and approximately $5.0 million (€4.1 million) in estimated offering expenses.

The Company expects to use the net proceeds from the Global Offering to advance the overall development of NBTXR3, prioritizing the treatment of locally advanced head and neck cancers, as follows (assuming an exchange rate of €1.00 = $1.2115, the exchange rate on December 10, 2020):

approximately $48.5 million (€40 million) to advance its clinical trial of NBTXR3 in the United States and Europe for the treatment of locally advanced head and neck cancers through an interim analysis of efficacy data,
approximately $18.2 million (€15 million) to advance the development of its other clinical and pre-clinical programs, and
the remainder for working capital funding and other general corporate purposes.

As of September 30, 2020, the Company had cash and cash equivalents of €42.4 million (non audited). The Company believes that the net proceeds from the Global Offering, together with its cash and cash equivalents, will be sufficient to fund its operations through the first quarter of 2023.

Underwriting

The Global Offering is subject to an underwriting agreement entered into on December 10, 2020. The underwriting agreement does not constitute a “garantie de bonne fin” within the meaning of Article L. 225-145 of the French Commercial Code (Code de commerce).

Documentation

The Company has filed a registration statement, including a prospectus, relating to these securities with the U.S. Securities and Exchange Commission (“SEC”), which was declared effective by the SEC on December 10, 2020. The securities referred to in this press release will be offered only by means of a prospectus in the United States. Copies of the final prospectus relating to and describing the terms of the Global Offering can be obtained, when available, from Jefferies LLC, 520 Madison Avenue New York, NY 10022, or by telephone at 877-547-6340 or 877-821-7388, or by email at [email protected]; or from Evercore Group L.L.C., Attention: Equity Capital Markets, 55 East 52nd Street, 35th Floor, New York, New York 10055, or by telephone at 888-474-0200, or by email at [email protected]; or from UBS Securities LLC, Attention: Prospectus Department, 1285 Avenue of the Americas, New York, New York 10019, or by telephone at 888-827-7275, or by email at [email protected].

Application will be made to list the New Shares on the regulated market of Euronext in Paris pursuant to a listing prospectus subject to an approval from the French Autorité des Marchés Financiers (“AMF”) and comprising the 2019 Universal Registration Document (Document d’Enregistrement Universel) of the Company filed with the AMF on May 12, 2020 under number R.20-010, as completed by a first amendment to such Universal Registration Document filed with the AMF on November 20, 2020 under number D.20-0339-A01 and a second amendment to such Registration Document, which will be filed on December 11, 2020 as well as a Securities Note (Note d’opération), including a summary of the prospectus. Following the filing of the second amendment to the 2019 Universal Registration Document, copies of the 2019 Universal Registration Document, as amended, will be available free of charge at the Company’s head office located at 60 rue de Wattignies, 75012 Paris, France, on the Company’s website (www.nanobiotix.com) and on the AMF’s website (www.amf-france.org).

The final prospectus will also be available at www.sec.gov. This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

Risk Factors

Investors should carefully consider the risk factors likely to affect the Company’s business as described in Section 1.5 “Risk Factors” in the 2019 Universal Registration Document, in Section 3 “Risk Factors” of the first amendment to the 2019 universal registration document and in Section 4 “Risk Factors” of the second amendment to the 2019 universal registration document expected to be filed with the AMF on December 11, 2020 before making an investment decision. If any of these risks are realized, the Company’s business, financial condition, operating results and prospects could be materially and adversely affected. In addition, other risks, not identified or considered significant by the Company, could have the same adverse effect and investors could lose all or part of their investment.

Allocation of the Share Capital

The following table presents the expected allocation of the Company’s share capital following the settlement and delivery of the New Shares (5,445,000 of which are ordinary shares represented by ADSs):

	Situation before the capital increase (on a non-diluted basis)			Situation after the capital increase (on a non-diluted basis and excluding the exercise of the over-allotment option)
Shareholders	Number of shares	% of share capital	% of voting rights	Number of shares	% of share capital	% of voting rights
Institutional Investors	8,758,377	33.64%	32.39%	14,518,676	43.55%	42.28%
Amiral Gestion	1,418,179	5.45%	5.25%	1,479,619	4.44%	4.31%
Baillie Gifford	409,836	1.57%	1.52%	1,888,097	5.66%	5.50%
Retail	13,734,003	52.75%	50.80%	13,734,003	41.20%	40.00%
Management	962,613	3.70%	6.06%	962,613	2.89%	4.77%
including Laurent Levy	809,060	3.11%	5.10%	809,060	2.43%	4.02%
Employees (excl. management)	450,211	1.73%	2.87%	450,211	1.35%	2.26%
Family offices and others	298,388	1.15%	1.10%	298,388	0.90%	0.87%
Liquidity Contract	5,515	0.02%	0.02%	5,515	0.02%	0.02%
Total	26,037,122	100.00%	100.00%	33,337,122	100.00%	100.00%

About NANOBIOTIX

Incorporated in 2003, Nanobiotix is a leading, clinical-stage nanomedicine company pioneering new approaches to significantly change patient outcomes by bringing nanophysics to the heart of the cell.

The Nanobiotix philosophy is rooted in designing pioneering, physical-based approaches to bring highly effective and generalized solutions to address unmet medical needs and challenges.

Nanobiotix’s novel, proprietary lead technology, NBTXR3, aims to expand radiotherapy benefits for millions of cancer patients. Nanobiotix’s Immuno-Oncology program has the potential to bring a new dimension to cancer immunotherapies.

Nanobiotix is listed on the regulated market of Euronext in Paris (Euronext: NANO / ISIN: FR0011341205; Bloomberg: NANO: FP). Its headquarters are in Paris, France. Nanobiotix has a subsidiary, Curadigm, located in France and the United States, as well as a US affiliate in Cambridge, MA, and European affiliates in France, Spain and Germany.

Disclaimer

This press release contains certain forward-looking statements concerning the Global Offering as well as Nanobiotix and its business, including its prospects and product candidate development. Such forward-looking statements are based on assumptions that Nanobiotix considers to be reasonable. However, there can be no assurance that the estimates contained in such forward-looking statements will be verified, which estimates are subject to numerous risks including the risks set forth in the universal registration document of Nanobiotix registered with the AMF under number R.20-010 on May 12, 2020 and in a first amendment filed with the AMF under number D.20-0339-A01 on November 20, 2020 (copies of which are available on www.nanobiotix.com) and a second amendment to such Registration Document, which will be filed on December 11, 2020 and to the development of economic conditions, financial markets and the markets in which Nanobiotix operates. The forward-looking statements contained in this press release are also subject to risks not yet known to Nanobiotix or not currently considered material by Nanobiotix. The occurrence of all or part of such risks could cause actual results, financial conditions, performance or achievements of Nanobiotix to be materially different from such forward-looking statements.

This press release does not constitute an offer to sell nor a solicitation of an offer to buy, nor shall there be any sale of ordinary shares or ADSs of Nanobiotix in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

The distribution of this document may, in certain jurisdictions, be restricted by local legislations. Persons into whose possession this document comes are required to inform themselves about and to observe any such potential local restrictions.

European Economic Area

In relation to each Member State of the European Economic Area (each, a ‘‘Member State’’) no offer to the public of ordinary shares and ADSs may be made in that Member State other than:

– to any legal entity which is a ‘‘qualified investor’’ as defined in the Prospectus Regulation;

– to fewer than 150 natural or legal persons (other than a qualified investor as defined in the Prospectus Regulation); or

– in any other circumstances falling within Article 1(4) of the Prospectus Regulation,

provided that no such offer of ordinary shares and ADSs shall require us or any Underwriter to publish a prospectus pursuant to Article 3 of the Prospectus Regulation or supplement a prospectus pursuant to Article 23 of the Prospectus Regulation and each person who initially acquires any shares or to whom any offer is made will be deemed to have represented, acknowledged and agreed to and with each of the Underwriters and the Company that it is a ‘‘qualified investor’’ as defined in the Prospectus Regulation.

For the purposes of this provision, the expression an ‘‘offer to the public’’ in relation to any ordinary shares and ADSs in any Member State means the communication in any form and by any means of sufficient information on the terms of the offer and any ordinary shares and ADSs to be offered so as to enable an investor to decide to purchase any ordinary shares and ADSs, and the expression ‘‘Prospectus Regulation’’ means Regulation (EU) 2017/1129 (as amended).

France

The ADSs and the ordinary shares have not been and will not be offered or sold to the public in the Republic of France, and no offering of this prospectus or any marketing materials relating to the ADSs and the ordinary shares may be made available or distributed in any way that would constitute, directly or indirectly, an offer to the public in the Republic of France (except for public offerings defined in Article L.411-2 1° of the French Code monétaire et financier).

The ordinary shares in the form of ADSs may only be offered or sold in France pursuant to article L. 411-2 1° of the French Code monétaire et financier to qualified investors (as such term is defined in Article 2(e) of Regulation (EU) n° 2017/1129 dated 14 June 2017, as amended) acting for their own account, and in accordance with articles L. 411-1, L. 411-2 and D. 411-2 to D.411-4, D.744-1 and D. 754-1 and D. 764-1 of the French Code monétaire et financier.

This announcement is not an advertisement and not a prospectus within the meaning of the Prospectus Regulation.

This press release has been prepared in both French and English. In the event of any differences between the two texts, the French language version shall supersede.

View source version on businesswire.com: https://www.businesswire.com/news/home/20201210006268/en/

Nanobiotix

Communications Department

Brandon Owens

VP, Communications

+1 (617) 852-4835

[email protected]

Investor Relations Department

Ricky Bhajun

Senior Manager, Investor Relations

+33 (0)1 79 97 29 99

[email protected]

Media Relations

France – Ulysse Communication

Pierre-Louis Germain

+ 33 (0)6 64 79 97 51

[email protected]

US – Porter Novelli

Scott Stachowiak

+1 (212) 601 8000

KEYWORDS: Massachusetts Europe United States North America France

INDUSTRY KEYWORDS: Oncology Health Clinical Trials Research Science Pharmaceutical Biotechnology

MEDIA:

Logo

December 11, 2020 2:11 am

OncoZenge raises MSEK 10 ahead of spin-off and separate listing

PR Newswire

STOCKHOLM, Dec. 11, 2020 /PRNewswire/ — OncoZenge AB (publ) (“OncoZenge”), Moberg Pharma AB (publ)’s subsidiary, has today resolved on a directed share issue in accordance with the press release from November 16^th, 2020 (the “Directed Issue”). The Directed Issue of MSEK 10 is the first step of the secured financing in OncoZenge of MSEK 70 in total. The share issue is carried out to secure OncoZenge’s initial working capital requirements ahead of the listing on Nasdaq First North Growth Market, which is planned to take place during the first quarter of 2021.

On November 16^th, 2020, it was announced that OncoZenge, through binding commitments, has secured financing in a total amount of approximately MSEK 70 ahead of its spin-off and separate listing, of which MSEK 10 through the Directed Issue and the remaining approximately MSEK 60 through a rights issue in connection with the contemplated separate listing of OncoZenge.

The Board of Directors of OncoZenge has today, based on the authorization from an extraordinary general meeting on November 16^th, 2020, resolved to carry out the Directed Issue. In total, OncoZenge will issue no more than 100,000 shares at a subscription price of SEK 100 per share, which means that OncoZenge will receive issue proceeds in an amount of no more than MSEK 10. The largest investors in the Directed Issue are John Fällström, Linc AB and Östersjöstiftelsen. Based on the subscription price in the Directed Issue, the value of OncoZenge before the Directed Issue amounts to approximately MSEK 50. Subscription and payment of the new shares will take place in December 2020.

Following the Directed Issue, the total number of shares and votes in OncoZenge will amount to 600,000 shares and votes. The dilution effect for the current shareholders in OncoZenge will be approximately 16.7 percent. The reason for the deviation from the shareholders’ preferential rights is to raise adequate working capital in a time and cost-efficient manner, to broaden OncoZenge’s shareholder base and to secure investment commitments for the remaining MSEK 60 ahead of the listing.

For the financing of an upcoming clinical phase 3 study and other activities, OncoZenge also intends to carry out a fully guaranteed rights issue, which is expected to raise approximately MSEK 60 to the Company before costs. The valuation in the rights issue will be approximately MSEK 60, i.e. the same valuation as in the Directed Issue, adjusted for the issue proceeds of MSEK 10. The subscription period for the rights issue is expected to commence directly after the first day of trading in OncoZenge’s shares. Further details on the terms and the timetable is intended to be announced in January 2021.

For additional information, please contact:

Anna Ljung, CEO Moberg Pharma, telephone: +46 707 66 60 30, e-mail: [email protected]
Pirkko Tamsen, CEO OncoZenge, telephone: +46 760 09 84 99, e-mail: [email protected]

About this information

The information was submitted for publication, through the agency of the contact persons set out above, at 8.00 a.m. CET on December 11^th, 2020.

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/moberg-pharma/r/oncozenge-raises-msek-10-ahead-of-spin-off-and-separate-listing,c3252554

The following files are available for download:

https://mb.cision.com/Main/1662/3252554/1346838.pdf

OncoZenge raises MSEK 10 ahead of spin-off and separate listing

View original content:http://www.prnewswire.com/news-releases/oncozenge-raises-msek-10-ahead-of-spin-off-and-separate-listing-301191019.html

SOURCE Moberg Pharma

December 11, 2020 2:08 am

OneConnect Enables Fintech Innovation in Abu Dhabi Global Market’s Digital Lab

PR Newswire

SHENZHEN, China, Dec. 11, 2020 /PRNewswire/ — Leading technology-as-a-service platform provider OneConnect Financial Technology Co., Ltd. (NYSE: OCFT) (“OneConnect” or “the Company”) was recognized at the recent FinTech Abu Dhabi Festival for its technological support of ADGM Digital Lab, a platform of Abu Dhabi Global Market (ADGM), the award-winning International Financial Center.

In April, OneConnect, an associate company of Ping An Insurance Group, signed a cooperative agreement with ADGM to provide technological support for the construction of ADGM Digital Lab, which is a “digital market” that focuses on financial businesses. The key role of the Digital Lab is to provide a virtual platform and resources such as data, application programming interfaces (APIs), system images and reference architectures. On the platform, financial institutions and Fintech firms can collaborate to implement agile iterations and test for innovative financial solutions.

The technology used by OneConnect to support the construction of ADGM Digital Lab is derived from Gamma O, OneConnect’s own open platform aiming to link developers, Fintech services providers and financial institutions. In addition to sharing advanced technology and Fintech platform, Gamma O also provides a sandbox testing environment to drive the innovative transformation of financial institutions.

“The ADGM Digital Lab provides a secure and reliable digital environment that allows Fintech companies to work with financial institutions to create and test solutions to solve real-world problems,” said H.E. Ahmed Ali Al Sayegh, chairman of ADGM, in his remarks at the FinTech Abu Dhabi Festival.

Under the supervision of the central bank and financial institutions in Abu Dhabi, the ADGM Digital Lab enables players in the industry — including financial institutions, startups, regulators, tech vendors, academics, venture capitalists and government entities — to identify and address shared challenges together.

H.E. Al Sayegh said that despite the challenging situation as a result of the pandemic this year, the number of tech start-ups at ADGM grew by 80 per cent to 291 and venture capital activity tripled from the prior year.

The platform symbolizes the latest development of strategic relationships between OneConnect and ADGM to build a comprehensive digital financial and business services ecosystem. The agreement is expected to bring more business opportunities to Middle East and North African countries along the One Belt One Road initiative and boost the development of local Fintech innovations.

OneConnect is at the forefront of Fintech. As of June 30, OneConnect had obtained 4,327 patents, 945 of which were overseas patents, and served over 50 international customers in over 15 markets.

About OneConnect

OneConnect is a leading technology-as-a-service platform for financial institutions in China. The Company’s platform provides cloud-native technology solutions that integrate extensive financial services industry expertise with market-leading technology. The Company’s solutions provide technology applications and technology-enabled business services to financial institutions. Together they enable the Company’s customers’ digital transformations, which help them increase revenue, manage risks, improve efficiency, enhance service quality, and reduce costs.

Our technology-as-a-service platform strategically covers multiple verticals in the financial services industry, including banking, insurance and asset management, across the full scope of their businesses – from sales and marketing and risk management to customer services, as well as technology infrastructures such as data management, program development, and cloud services.

View original content:http://www.prnewswire.com/news-releases/oneconnect-enables-fintech-innovation-in-abu-dhabi-global-markets-digital-lab-301191018.html

SOURCE OneConnect

December 11, 2020 2:03 am

Voyager Completes Merger with LGO Positioning Company with Fully Regulated European Platform

PR Newswire

CSE: VYGR
OTCQB: VYGVF
Borse Frankfurt: UCD2

– Voyager’s European platform to commence operations in 2021 –

NEW YORK, Dec. 11, 2020 /PRNewswire/ – Voyager Digital Ltd. (“Voyager” or the “Company”) (CSE: VYGR) (OTCQB: VYGVF) (FRA: UCD2), a publicly traded, licensed crypto-asset broker that provides investors with a turnkey solution to trade and earn interest on crypto assets, today announced that it has closed on the previously announced merger of its European operations into LGO, SAS, an entity regulated by the AMF, France’s stock market regulatory authority. The merger gives Voyager direct control of the regulated entity which will allow the Company to expedite its European strategy.

“This merger gives Voyager the ability to service the 750 million European population with the most consumer-friendly agency brokerage platform for investing in crypto assets,” said Steve Ehrlich, Co-founder and CEO of Voyager. “We look forward to our international expansion as Voyager’s growth continues on all fronts, with AUM growing rapidly and our product offering continually enhanced with debit and credit card, margin, and more traditional banking products on the horizon. We look forward to making Voyager a truly global company and having Gaspard de Dreuzy lead the integration efforts in Europe.”

With the closing completed, Voyager can now finalize the next version of the Voyager token in conjunction with a token swap, allowing holders of the VGX and LGO token to exchange to the new token. The token swap is expected to be completed in the first quarter of 2021. The new token includes decentralized finance features such as community governance, and also advanced utility including staking with an initial 7% interest, cashback rewards on trading on the Voyager platform, debit card benefits, interest boosters, reduction of withdrawal fees, and more, all on a global basis.

“We are excited to create an improved token to bring greater utility to our loyal community. Historic holders of VGX have benefited from our rewards programs and interest boosters. Now with the new coin, holders will enjoy additional features over time,” stated Mr. Ehrlich.

Voyager will issue LGO 200,000 shares at closing and up to 1 million more upon certain conditions being met, with the 1 million shares held in escrow.

Just recently, Voyager announced its 55th digital asset on its platform and that assets under management have exceeded $165 million, with plans to continue to grow the asset base on the platform.

For more information on Voyager Digital, please visit https://www.investvoyager.com. The Voyager App is available for Android and iPhone.

About Voyager Digital Ltd.
Voyager Digital Ltd. is a crypto-asset broker that provides retail and institutional investors with a turnkey solution to trade crypto assets. Voyager offers customers best execution and safe custody on a wide choice of popular crypto-assets. Voyager was founded by established Wall Street and Silicon Valley entrepreneurs who teamed to bring a better, more transparent, and cost-efficient alternative for trading crypto-assets to the marketplace. Please visit us at https://www.investvoyager.com for more information and to review the latest Corporate Presentation.

Neither the Canadian Securities Exchange nor its Market Regulator (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release. No securities regulatory authority has either approved or disapproved of the contents of this press release.

Cautionary Statement regarding Forward-Looking Information: The forward-looking statements contained herein are made as of the date of this release and, other than as required by applicable securities laws, the Company does not assume any obligation to update or revise it to reflect new events or circumstances. The forward-looking statements contained in this release are expressly qualified by this cautionary statement.

View original content to download multimedia:http://www.prnewswire.com/news-releases/voyager-completes-merger-with-lgo-positioning-company-with-fully-regulated-european-platform-301190929.html

SOURCE Voyager Digital (Canada) Ltd.

December 11, 2020 2:03 am

Adding green energy to the grid: Philips, HEINEKEN, Nouryon and Signify form first Pan-European consortium for future wind farm

December 11, 2020

Consortium supports the development of additional 126 Megawatt capacity at wind farm in Finland
Driving incremental production of renewable electricity in Europe, the deal is expected to add 330 Gigawatt hours of clean power to the electricity grid
Netherlands-headquartered HEINEKEN, Nouryon, Philips and Signify committed to contracting renewable electricity from the wind farm for the first 10 years through a virtual Power Purchase Agreement (virtual PPA)

Amsterdam, the Netherlands – Royal Philips, HEINEKEN, Nouryon and Signify have formed the first consortium to sign a Pan-European green energy deal securing additional renewable electricity for Europe. The four companies have a shared vision to further reduce CO₂ emissions in support of the UN Paris Agreement and the European Green Deal objectives.

The companies joined forces to support the development of 35 wind turbines in the Mutkalampi municipality in Finland, which is scheduled for completion in 2023. The virtual PPA covers an expected output volume of 330 GWh per year – equivalent to the electricity consumption of 40,000 households. Compared to the average European electricity generation, this renewable electricity will help to avoid over 230,000 tons of CO₂ emissions per year.

The consortium has committed to contracting renewable electricity from the wind farm for the first 10 years through a virtual PPA. The electricity will be physically delivered to the Finnish grid while the four consortium partners benefit from the Guarantees of Origin. This provides income stability for the renewable project while guaranteeing clean energy benefits for the corporate buyers.

While the companies have signed PPAs for renewable electricity in the past, this is the first time such a consortium has formed a virtual PPA to drive incremental renewable electricity for Europe.

Through this consortium, HEINEKEN will source renewable electricity for an additional 31 of its European production sites [1], Nouryon will continue its progress in reducing CO₂emissions by 25% by 2025, Philips secures renewable electricity supply to power its European operations for a 10-year period and Signify solidifies its leading position on 100% renewable electricity use and doubling the pace to reach the Paris Agreement over their value chain by 2025.

Jorge Paradela, Corporate Affairs Director Europe at HEINEKEN: “As part of our global CO₂ reduction program, Drop the C, we aim to significantly reduce emissions across our value chain and are committed to reaching 70% renewable energy in the production of our beers by 2030. This virtual PPA is another step towards our ambition and will provide the equivalent electricity needed to brew over 5 billion bottles of beer. Where possible, we aim to develop local PPAs for our Operating Companies. For example HEINEKEN Spain has signed a long term PPA involving the construction of a new solar photovoltaic plant. It is not always possible to build locally, therefore we are delighted to join forces on this virtual PPA to deliver significant renewable electricity for Europe. We firmly believe in the power of collaboration to help contribute to a greener world and greener future for us all.”

Marcel Galjee, Vice President Energy & New Business at Nouryon Industrial Chemicals: “As part of our commitment to a sustainable future, we have set a target to reduce carbon emissions by 25% between 2020 and 2025 and to increase our share of renewable and low-carbon energy to 60%. This virtual PPA combines the best of both worlds: additional renewable electricity is realized in Finland where there is space, both physically and on the grid, while we benefit from more sustainable energy for our operations.”

Robert Metzke, Global Head of Sustainability at Philips: “Climate change threatens our healthcare systems globally. This renewable electricity partnership raises the bar in how we can jointly increase green energy supply across Europe, in line with the UN Paris Agreement. With this agreement, we secure renewable electricity supply to power our global operations for a 10-year period, delivering real progress on our 2025 climate targets. By the end of this year, we will be carbon neutral in our own operations, and we aim to source over 75% of our total energy consumption from renewable sources by 2025.”

Nicola Kimm, Head of Sustainability, Environment, Health & Safety at Signify: “The world increasingly faces the challenges posed by climate change. The time to act is now. We already achieved carbon neutrality for all our global operations earlier this year and we source 100% renewable electricity. Now we are committing to double the pace we reach the Paris Agreement over our value chain by 2025. Joining forces to realize this Pan-European PPA will accelerate the transition to clean energy and supports our climate action ambitions. We hope to encourage others to follow so we can collectively reduce carbon emissions around the globe.”

The new wind farm will be realized by Neoen, an independent French producer of renewable energy. The four parties were advised on the consortium by Schneider Electric.

[1] Across 13 of its European Operating Companies in Romania, Portugal, Belgium, Bulgaria, Croatia, Czech Republic, Greece, Hungary, Ireland, Serbia, Slovakia, Slovenia and Switzerland.

About Royal Philips
Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people’s health and well-being, and enabling better outcomes across the health continuum – from healthy living and prevention, to diagnosis, treatment and home care. Philips leverages advanced technology and deep clinical and consumer insights to deliver integrated solutions. Headquartered in the Netherlands, the company is a leader in diagnostic imaging, image-guided therapy, patient monitoring and health informatics, as well as in consumer health and home care. Philips generated 2019 sales of EUR 19.5 billion and employs approximately 81,000 employees with sales and services in more than 100 countries. News about Philips can be found at www.philips.com/newscenter.

About Heineken

HEINEKEN is the world’s most international brewer. It is the leading developer and marketer of premium beer and cider brands. Led by the Heineken® brand, the Group has a portfolio of more than 300 international, regional, local and specialty beers and ciders. HEINEKEN is committed to innovation, long-term brand investment, disciplined sales execution and focused cost management. Through “Brewing a Better World”, sustainability is embedded in the business. HEINEKEN has a well-balanced geographic footprint with leadership positions in both developed and developing markets. It employs over 85,000 employees and operates breweries, malteries, cider plants and other production facilities in more than 70 countries. Heineken N.V. and Heineken Holding N.V. shares trade on the Euronext in Amsterdam. Prices for the ordinary shares may be accessed on Bloomberg under the symbols HEIA NA and HEIO NA and on Reuters under HEIN.AS and HEIO.AS. HEINEKEN has two sponsored level 1 American Depositary Receipt (ADR) programmes: Heineken N.V. (OTCQX: HEINY) and Heineken Holding N.V. (OTCQX: HKHHY). Most recent information is available on HEINEKEN’s website: www.theHEINEKENcompany.com and follow us via @HEINEKENCorp.

About Nouryon

We are a global specialty chemicals leader. Markets worldwide rely on our essential chemistry in the manufacture of everyday products, such as paper, plastics, building materials, food, pharmaceuticals, and personal care items. Building on our nearly 400-year history, the dedication of our 10,000 employees, and our shared commitment to business growth, strong financial performance, safety, sustainability, and innovation, we have established a world-class business and built strong partnerships with our customers. We operate in over 80 countries around the world and our portfolio of industry-leading brands includes Eka, Dissolvine, Trigonox and Berol. Visit our website and follow us @Nouryon and on LinkedIn.

About Signify

Signify
(Euronext: LIGHT) is the world leader in lighting for professionals and consumers and lighting for the Internet of Things. Our Philips products, Interact connected lighting systems and data-enabled services, deliver business value and transform life in homes, buildings and public spaces. With 2019 sales of EUR 6.2 billion, we have approximately 37,000 employees and are present in over 70 countries. We unlock the extraordinary potential of light for brighter lives and a better world. We achieved carbon neutrality in 2020, have been in the Dow Jones Sustainability World Index since our IPO for four consecutive years and were named Industry Leader in 2017, 2018 and 2019. News from Signify is located at the Newsroom, Twitter, LinkedIn and Instagram. Information for investors can be found on the Investor Relations page.

Attachment

First Pan-European consortium for future wind farm

December 11, 2020 2:03 am

Falcon Oil & Gas Ltd. – Results of Annual General & Special Shareholders Meeting

FALCON OIL & GAS LTD.

(“Falcon”)

Results of Annual General & Special Shareholders Meeting

11 December 2020 – Falcon Oil & Gas Ltd. (TSXV: FO, AIM: FOG) held its Annual General & Special Shareholders meeting via conference call yesterday, 10 December 2020.

All resolutions considered and voted upon by the shareholders were approved. The full text of each resolution was included in the Management Information Circular communicated in advance of the meeting to shareholders.

The Annual General & Special Shareholders meeting presentation is available on the Falcon website at https://falconoilandgas.com/.

For further information, please contact:

CONTACT DETAILS:

Falcon Oil & Gas Ltd.	+353 1 676 8702
Philip O’Quigley, CEO	+353 87 814 7042
Anne Flynn, CFO	+353 1 676 9162

Cenkos Securities plc (NOMAD & Broker)
Neil McDonald / Derrick Lee	+44 131 220 9771

About Falcon Oil & Gas Ltd.

Falcon Oil & Gas Ltd is an international oil & gas company engaged in the exploration and development of unconventional oil and gas assets, with the current portfolio focused in Australia, South Africa and Hungary. Falcon Oil & Gas Ltd is incorporated in British Columbia, Canada and headquartered in Dublin, Ireland with a technical team based in Budapest, Hungary.

For further information on Falcon Oil & Gas Ltd. please visit www.falconoilandgas.com

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Certain information in this press release may constitute forward-looking information. This information is based on current expectations that are subject to significant risks and uncertainties that are difficult to predict. Actual results might differ materially from results suggested in any forward-looking statements. Falcon assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those reflected in the forward looking-statements unless and until required by securities laws applicable to Falcon. Additional information identifying risks and uncertainties is contained in Falcon’s filings with the Canadian securities regulators, which filings are available at www.sedar.com.

December 11, 2020 2:03 am

Ahold Delhaize announces €1 billion Sustainability-Linked Revolving Credit Facility

Zaandam, the Netherlands,
December 11
, 20
20 – Ahold Delhaize today announces that it has successfully closed a €1 billion, Sustainability-linked Revolving Credit Facility (the ‘Facility’), refinancing its existing 2015-dated €1 billion facility. The Facility is an important milestone that highlights how Ahold Delhaize is reinforcing the alignment of its funding strategy and its commitments laid out in its Healthy & Sustainable ambition, which can be found here

Through this Facility, Ahold Delhaize draws a connection between its cost of borrowing and the achievement of the following ambitions:

Food waste reduction: as measured by percentage reduction in tons of food waste per million Euro food sales and supporting the UN SDG 12.3;

Carbon emission reduction: as measured by percentage reduction of Scope 1 and Scope 2 CO2-equivalent emissions and aligned with Ahold Delhaize SBTi-certified 2030 targets;

Promotion of healthier eating: as measured by percentage of own brand food sales from healthy products.

Ahold Delhaize will report on the progress on these ambitions in the company’s annual report.

Natalie Knight, Chief Financial Officer, said: “This is an important facility for Ahold Delhaize that ensures we maintain our financial flexibility. After having issued the first euro-denominated Sustainability Bond in the Retail industry in June 2019, we believe that linking this facility with our significant Healthy & Sustainable ambition will deliver a positive outcome for all stakeholders.”

The new Facility has a maturity of three years with two one-year extension options. The Facility also includes a mechanism allowing the company to anticipate the discontinuation of the US dollar interbank benchmark interest rate. A syndicate of 16 relationship banks participate in the Facility.

ABN AMRO and Société Générale acted as Coordinators and Sustainability Coordinators on the Facility.

Cautionary notice
This communication includes forward-looking statements. All statements other than statements of historical facts may be forward-looking statements. Words such as reinforcing, alignment, strategy, commitments, ambition(s), reduction, promotion, progress, ensures, maintain, believe, deliver, outcome, maturity, options, anticipate, discontinuation or other similar words or expressions are typically used to identify forward-looking statements.

Forward-looking statements are subject to risks, uncertainties and other factors that are difficult to predict and that may cause actual results of Koninklijke Ahold Delhaize N.V. (the “Company”) to differ materially from future results expressed or implied by such forward-looking statements. Such factors include, but are not limited to, the risk factors set forth in the Company’s public filings and other disclosures. Forward-looking statements reflect the current views of the Company’s management and assumptions based on information currently available to the Company’s management. Forward-looking statements speak only as of the date they are made and the Company does not assume any obligation to update such statements, except as required by law.

December 11, 2020 1:33 am

Nicox’s Partner Fera Pharmaceuticals to Investigate Naproxcinod as Potential Covid-19 Adjuvant Treatment

Press Release
Nicox’s Partner Fera Pharmaceuticals to Investigate Naproxcinod as Potential Covid-19 Adjuvant Treatment
December 11, 2020 – release at 7:30 am CET Sophia Antipolis, France Nicox SA (Euronext Paris: FR0013018124, COX), an international ophthalmology company, and Fera Pharmaceuticals, a privately-held, U.S. specialty pharmaceutical company, announced today that Fera will evaluate naproxcinod as a potential adjuvant treatment for patients with COVID-19 infection. Subject to successful completion of the ongoing manufacturing of naproxcinod test material, Fera plans to initiate pre-clinical proof-of-concept studies in models of COVID-19 infection in early 2021. Naproxcinod, a Cyclooxygenase-Inhibiting Nitric Oxide (NO)-Donating (CINOD) naproxen, is a non-steroidal anti-inflammatory product candidate engineered to release NO and naproxen, originally discovered and developed by Nicox. Nicox and Fera entered into an agreement in December 2015 which granted Fera exclusive rights to develop and commercialize naproxcinod for the U.S. market. Nicox and Fera are amending their existing agreement to include COVID-19 as an indication, and Nicox will grant to Fera warrants¹ to acquire 10,000 Nicox shares. Michele Garufi, Chief Executive Officer and Chairman of Nicox, said: “There is a strongscientific rationale for using naproxcinod in the treatment of the inflammatory symptoms of COVID-19 infections, and potentially against the virus itself. In collaboration with Fera we will be testing this scientific rationale in relevant pre-clinical models and whilst this research is at an early stage, any potential future human trial would benefit from the extensive naproxcinod clinical data previously generated by Nicox for the treatment of signs and symptoms of osteoarthritis.” Rationale for naproxcinod in COVID-19 treatment Most outcomes of COVID-19 are associated with high levels of inflammation and dysfunction of the vascular system leading to thrombotic events². Naproxcinod, a Cox-Inhibiting Nitric Oxide Donor (CINOD), would potentially treat multiple aspects of COVID-19 infection including fever, pain, inflammation and platelet aggregation, thus decreasing the risk of thrombus formation. In addition, NO donation might increase vasodilation and restore normal vascular functions. Moreover, NO has specifically been demonstrated to inhibit replication of the COVID-19 virus by two distinct mechanisms³. As an oral capsule formulation, naproxcinod could be easily administered to patients at the first signs of infection. Once Fera has received the newly manufactured naproxcinod, they plan to initiate proof-of-concept pre-clinical tests in models of COVID-19 infection. Should the results of these studies prove positive, Fera plans to meet with the U.S. Food and Drug Administration (FDA) to identify the clinical trials that would be required to submit a New Drug Application (NDA) for naproxcinod in the treatment of COVID-19 infection. Under the terms of the naproxcinod agreement with Nicox, Fera is responsible for all clinical development, manufacturing, regulatory and commercialization activities in the U.S. Nicox retains all rights to naproxcinod outside the U.S., subject to the payment of royalties to Fera, if intellectual property developed under the agreement is used outside the U.S. Fera continues to review non-COVID-19 development options for naproxcinod, including addressing the U.S. FDA refusal letter concerning Fera’s application for Orphan Drug Designation (ODD) of naproxcinod in sickle-cell disease.
About naproxcinod
Naproxcinod is a nitric oxide (NO)-donating naproxen combining the cyclooxygenase (COX) inhibitory activity of naproxen with that of NO (COX-inhibiting NO donor, CINOD). While the inhibitory COX component provides the analgesic and anti-inflammatory efficacy, the NO part may play a significant role in maintaining vascular endothelial cell function and integrity, blood pressure homeostasis and microvascular circulation. A broad clinical package already exists for naproxcinod in osteoarthritis, including three phase 3 trials with over 2,700 patients.
About Fera Pharmaceuticals
Fera Pharmaceuticals is a privately held company. The company goal is to realize opportunities via acquisitions, in-licensing, developing and marketing abbreviated new drug applications (ANDAs), new drug applications (NDAs) and 505(b)(2) NDA products. Areas of interest include products that could benefit from lifecycle management with a special focus on niche markets. For more information visit www.ferapharma.com.
About Nicox
Nicox S.A. is an international ophthalmology company developing innovative solutions to help maintain vision and improve ocular health. Nicox’s lead program in clinical development is NCX 470, a novel, second-generation nitric oxide-donating bimatoprost analog, for lowering intraocular pressure in patients with glaucoma. The company is also developing NCX 4251, a proprietary formulation of fluticasone, for acute exacerbations of blepharitis. Nicox generates revenue from VYZULTA® in glaucoma, licensed exclusively worldwide to Bausch + Lomb, and ZERVIATE™ in allergic conjunctivitis, licensed in multiple geographies, including to Eyevance Pharmaceuticals, LLC, in the U.S. and Ocumension Therapeutics in the Chinese and in the majority of South East Asian markets. Nicox is headquartered in Sophia Antipolis, France, is listed on Euronext Paris (Compartment B: Mid Caps; Ticker symbol: COX) and is part of the CAC Healthcare, CAC Pharma & Bio and Next 150 indexes. For more information on Nicox, its products or pipeline, please visit: www.nicox.com.
Analyst coverage
Bryan, Garnier & Co Victor Floc’h Paris, France Cantor Fitzgerald Louise Chen New York, U.S. H.C. Wainwright & Co Yi Chen New York, U.S. Kepler Cheuvreux Damien Choplain Paris, France Oppenheimer & Co Hartaj Singh New York, U.S.
The views expressed by analysts in their coverage of Nicox are those of the author and do not reflect the views of Nicox. Additionally, the information contained in their reports may not be correct or current. Nicox disavows any obligation to correct or to update the information contained in analyst reports.
Contacts
Nicox Gavin Spencer Executive Vice President, Chief Business Officer & Head of Corporate Development T +33 (0)4 97 24 53 00 [email protected]
Investors & Media United States & Europe LifeSci Advisors, LLC Mary-Ann Chang T +44 7483 284 853 [email protected]	Media France LifeSci Advisors, LLC Sophie Baumont M +33 (0)6 27 74 74 49 [email protected]
Forward-Looking Statements
The information contained in this document may be modified without prior notice. This information includes forward-looking statements. Such forward-looking statements are not guarantees of future performance. These statements are based on current expectations or beliefs of the management of Nicox S.A. and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Nicox S.A. and its affiliates, directors, officers, employees, advisers or agents, do not undertake, nor do they have any obligation, to provide updates or to revise any forward-looking statements. Risks factors which are likely to have a material effect on Nicox’s business are presented (i) in the 3^rd chapter of the ‘Document d’enregistrement universel, rapport financier annuel et rapport de gestion 2019’ filed with the French Autorité des Marchés Financiers (AMF) on March 6, 2020 which are available on Nicox’s website (www.nicox.com) and (ii) as restated in the 4^th chapter of the half yearly financial report as of June 30, 2020, which is also available on Nicox’s website.
Nicox S.A. Drakkar 2 Bât D, 2405 route des Dolines CS 10313, Sophia Antipolis 06560 Valbonne, France T +33 (0)4 97 24 53 00 F +33 (0)4 97 24 53 99

¹ The warrants will be issued at no cost. The subscription price of the new shares to be obtained by exercising the warrants will be equal to the VWAP calculated on the 3-days trading prior to the Board meeting that will decide on the issuance of the warrants.

² Bikdeli et al., COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-Up: JACC State-of-the-Art Review. J Am Coll Cardiol. 2020; 75(23):2950-2973.

³ S. Akerstrom et al., Dual effect of nitric oxide on SARS-CoV replication: Viral RNA production and palmitoylation of the S protein are affected. Journal of Virology 2009; 395:1–9.

Attachment

EN_FeraNaproxcinodCOVID_PR_F